What's new? Log in Free sign up

Mainz Biomed B.V. (MYNZ)

Company Profile

Company profile

Ticker

MYNZ

Exchange

Website

mainzbiomed.com

CEO

Mr. Guido Baechler

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

Mainz Biomed B.V.

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

MYNZ stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Prospectus supplement

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering

Notice of effectiveness

Registration statement (foreign) (amended)

Registration statement (foreign) (amended)

Report of Foreign Private Issuer

Report of Foreign Private Issuer

Registration statement (foreign)

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Latest ownership filings

Financial summary

Financial statements Chart MYNZ financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q2 2024

MYNZ institutional ownership history Ownership history

0.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	4	0	NEW
Opened positions	4	0	NEW
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	8.49 mm	0.00	NEW
Total shares	21.16 k	0.00	NEW
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Greenwich Investment Management	10.86 k	$4.36 mm	NEW
Wealth Quarterback	10.00 k	$4.01 mm	NEW
MS Morgan Stanley	200.00	$80.00 k	NEW
BAC Bank of America	100.00	$40.00 k	NEW
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Greenwich Investment Management	10.86 k	+10.86 k	NEW
Wealth Quarterback	10.00 k	+10.00 k	NEW
MS Morgan Stanley	200.00	+200.00	NEW
BAC Bank of America	100.00	+100.00	NEW
Proequities	0.00	0.00

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Mainz Biomed Forms Agreement With Quest Diagnostics To Support Commercialization Of Mainz Biomed's NextGen Screening Test For Colorectal Cancer

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today an agreement with Quest Diagnostics (NYSE:DGX), a

Mainz Biomed Announces 1-For-40 Stock Split; Expected To Begin Trading On The Split-Adjusted Basis At Market Open On December 3, 2024, Upon Nasdaq's Approval

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing

HC Wainwright & Co. Downgrades Mainz Biomed to Neutral

The Oncology Bet Is Already Paying Off For Pfizer

Press releases

From Benzinga Pro

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Detroit, Michigan--News Direct--By Meg Flippin, Benzinga Mainz Biomed N.V. (NASDAQ:MYNZ), the molecular genetics diagnostic company specializing in the early detection of cancer, is moving closer to commercializing its

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Mainz Biomed Announces Stock Split

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.